Get the Stockscreener App
6.25
1.63%
0.10
After Hours:
6.20
-0.05
-0.80%
Upstream Bio Inc stock is traded at $6.25, with a volume of 829.00K.
It is up +1.63% in the last 24 hours and down -26.56% over the past month.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$6.15
Open:
$6.26
24h Volume:
829.00K
Relative Volume:
1.25
Market Cap:
$340.12M
Revenue:
$3.32M
Net Income/Loss:
$-156.76M
P/E Ratio:
-2.1538
EPS:
-2.9019
Net Cash Flow:
$-140.13M
1W Performance:
-2.04%
1M Performance:
-26.56%
6M Performance:
-79.07%
1Y Performance:
-41.26%
1-Day Range:
$6.145
$6.52
1-Week Range:
$5.85
$6.52
52-Week Range:
$5.85
$33.68
Upstream Bio Inc Stock (UPB) Company Profile
Name
Upstream Bio Inc
Sector
Industry
Phone
781-208-2466
Address
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
6.25 | 334.68M | 3.32M | -156.76M | -140.13M | -2.9019 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 116.49B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 55.49B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 33.54B | 742.00K | -1.37B | -1.07B | -7.0731 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Nov-18-25 | Initiated | Evercore ISI | Outperform |
| Oct-14-25 | Initiated | Truist | Buy |
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
View All
Upstream Bio Inc Stock (UPB) Latest News
Top Executive Makes Strategic Move With Upstream Bio Stock - TipRanks
Upstream Bio Inc (UPB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Upstream Bio Inc (UPB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Upstream Bio Inc (UPB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Upstream Bio Inc (UPB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Upstream Bio Inc (UPB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Upstream Bio Inc (UPB) Institutional Confidence - TradingKey
Why Did UPB Stock Plunge 40% Today? - Stocktwits
Upstream Bio Inc (UPB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Upstream Bio presents positive Phase 2 trial data for verekitug By Investing.com - Investing.com Nigeria
Upstream Bio presents positive Phase 2 trial data for verekitug - Investing.com
Upstream Bio Reports Positive Phase 2 Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps, Achieving Clinically Meaningful Improvements in Key Symptoms - Quiver Quantitative
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements ... - Caledonian Record
Quarterly nasal polyp treatment improved symptoms for most trial patients - Stock Titan
Upstream Bio, Inc. unveils Phase 2 VIBRANT trial data showing majority of verekitug recipients achieve key improvements - Traders Union
Upstream Bio Inc. (UPB) Falls 4.39% as Shares Test Key Support LevelGamma Exposure - newsline.com
UPB Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Progress ContinuesEstimate Accuracy - newsline.com
Upstream Bio Cut to Neutral From Overweight by JP Morgan - Moomoo
Upstream Bio lead drug pivotal trial plan follows strong phase 2 data - MSN
JPMorgan Downgrades Upstream Bio to Neutral From Overweight, Cuts Price Target to $8 From $35 - marketscreener.com
JPMorgan downgrades Upstream Bio stock rating on execution risks By Investing.com - Investing.com Australia
J.P. Morgan Downgrades UpStream Bio(UPB.US) to Hold Rating, Announces Target Price $8 - Moomoo
UPB News | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
Upstream Bio Shareholders Elect Directors, Ratify 2026 Auditor - TipRanks
Upstream Bio, Inc. leadership to share strategy at major Goldman Sachs event - Traders Union
Upstream Bio (UPB) Declines 4% as Shares Approach Key Support at $6.42Thematic ETF Flow - newsline.com
Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026 - markets.businessinsider.com
Upstream Bio to present verekitug trial data at medical congress By Investing.com - Investing.com Australia
Upstream Bio to present verekitug trial data at medical congress - Investing.com
Upstream Bio, Inc. to present new Phase 2 VIBRANT trial data for verekitug at EAACI2026 - Traders Union
Upstream Bio To Showcase Additional Efficacy Data From The Phase 2 Vibrant Trial Of Verekitug In Crswnp In Oral Session At Eaaci 2026 - TradingView
Nasal polyp drug Verekitug Phase 2 data to be aired at EAACI 2026 - Stock Titan
Upstream Bio to Showcase Additional Efficacy Data from the - GlobeNewswire
Upstream Bio Inc. (UPB) Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Spark Investor ConfidenceFinancial Data - newsline.com
Upstream Bio (UPB) Edges Lower as Shares Test Key Support ZoneFundamentals - newsline.com
Upstream Bio (UPB) price target decreased by 18.03% to 51.00 - MSN
Upstream Bio schedules fireside chat at global healthcare event - Traders Union
H.C. Wainwright Initiates UpStream Bio(UPB.US) With Buy Rating, Announces Target Price $36 - Moomoo
UPB Initiates Coverage On HC Wainwright & Co. -- Rating Set to B - GuruFocus
UPB Initiates Coverage On HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - markets.businessinsider.com
H.C. Wainwright initiates Upstream Bio stock coverage with buy rating By Investing.com - Investing.com Canada
Upstream Bio: The Reset Is The Opportunity, Initiating At Buy (NASDAQ:UPB) - Seeking Alpha
Upstream Bio (UPB) price target decreased by 10.31% to 44.37 - MSN
Upstream Bio (UPB) Edges Higher Amid Quiet Trading, Holds Above Key SupportSupply Zone - The Legal Advocate
Upstream Bio Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical ProgressEarnings Surprise Score - The Legal Advocate
Upstream Bio Inc Stock (UPB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):